Jonathan MacQuitty focuses on life science and healthcare investments at Lightspeed. Jonathan has spent over 30 years in life science companies and in the venture capital sector that finances them. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office. Most recently he was the founding CEO of Forty Seven Inc, an immuno-oncology company based in Menlo Park, CA. Jonathan serves on the board of a number of Lightspeed companies and is Chairman of Personalis, which uses human genomic analysis for cancer research and treatment. He has also served on the Board of the Biotechnology Industry Organization (BIO). Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University.